The recommendation from Europe's Committee for Medicinal Products for Human Use (CHMP) bodes well for a final marketing authorization for the adalimumab biosimilar candidate.
Celltrion’s high-concentration, citrate-free adalimumab biosimilar candidate (CT-P17, Yuflyma) has been recommended for marketing authorization by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency. The European Commission, which authorizes medicinal products for the European Union, will make the final decision, but is strongly influenced by CHMP.
CT-P17 is intended for the treatment of 12 chronic inflammatory diseases, including rheumatoid arthritis (RA), psoriatic arthritis, and Crohn disease. CHMP recommended approval for all 12. Celltrion said the positive opinion is based on equivalency studies demonstrating efficacy, pharmacokinetics (PK), and overall safety compared with the reference product, Humira.
CT-P17 would be the first high-concentration (100 mg/mL), citrate-free adalimumab biosimilar. “Having a high-concentration and citrate-free formulation would provide patients less pain during administration leading to improved quality of life,” said Edward Keystone, MD, FRCPC, senior consultant rheumatologist at Mount Sinai Hospital in Toronto, Canada, in a statement.
There are at least 9 marketing-authorized versions of adalimumab in the European Union. There are 6 FDA-approved adalimumab biosimilars in the United States—but none of these is expected to reach market until 2023. A European Commission decision on the Celltrion product is expected in the first quarter of 2021.
The other proposed indications for CT-P17 are juvenile idiopathic arthritis, axial spondyloarthritis, psoriasis, pediatric plaque psoriasis, hidradenitis suppurativa, pediatric Crohn disease, ulcerative colitis, uveitis, and pediatric uveitis.
Results of a phase 3 study in patients with RA was presented at the American College of Rheumatology Convergence 2020. In the randomized study, CT-P17 met the primary objective of efficacy and safety comparable to the standard for the reference product.
Efficacy, PK, and safety equivalence to the reference product also were demonstrated in a separate, randomized, double-blind, single-dose phase 1 study in healthy individuals up to 10 weeks. “The CHMP positive opinion is very encouraging as CT-P17 has demonstrated promising study results in efficacy, PK and safety profile compared to reference adalimumab,” Keystone said.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.